OpenAI announced a partnership with Genmab, a biotechnology company, to deploy what the firms call "AI Everywhere" — an initiative embedding OpenAI's models across Genmab's research and development workflows [source].

The deployment, launched in September 2024, integrates ChatGPT Enterprise and custom GPT applications into Genmab's antibody discovery and clinical development processes. According to the announcement, the system assists scientists in literature review, protocol drafting, and data analysis tasks.

OpenAI's blog post describes the partnership as enabling "faster decision-making" and "accelerated timelines" in drug development. Genmab reports that early internal pilots reduced time spent on routine documentation tasks, though no quantitative metrics were disclosed in the public announcement.

The integration raises questions about model reliability in high-stakes scientific contexts. Biotechnology workflows involve interpreting complex datasets, regulatory requirements, and safety-critical decisions. OpenAI's models have previously exhibited hallucinations in technical domains, including fabricated citations and incorrect interpretations of scientific literature.

Neither OpenAI nor Genmab detailed what validation processes govern the AI-generated outputs, nor whether human review protocols are mandatory before outputs influence research decisions. The announcement does not specify which OpenAI models are deployed, whether fine-tuning was applied, or how the system handles uncertainty in ambiguous cases.

The partnership follows a pattern of OpenAI expanding into regulated industries — healthcare, legal, financial services — where output accuracy directly affects compliance and safety outcomes. Independent verification of AI-generated content in these domains remains a documented challenge, particularly when users lack domain expertise to identify subtle errors.

Genmab did not respond to questions about error rates or oversight mechanisms at the time of publication.